1-3 of 3
Paul Statkevich, PhD
Close
Sort by
Journal Articles

Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients

Robert A Baiocchi, MD, PhD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Kristie A. Blum, MD, Craig C. Hofmeister, MD, Jennifer Poon, PharmD, Karen Small, BSN, Paul Statkevich, PhD, Michael R. Grever, M.D., Rajat Bannerji, MD, PHD, John C. Byrd, MD
Journal: Blood
Blood (2010) 116 (21): 3966.
https://doi.org/10.1182/blood.V116.21.3966.3966
Published: 2010
Journal Articles

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Kristie A. Blum, MD, Amy J. Johnson, PhD, Josh Hessler, Elizabeth Wiley, Jennifer Poon, PharmD, Karen Small, BSN, Paul Statkevich, PhD, Michael R. Grever, M.D., Rajat Bannerji, MD, PhD, John C. Byrd, MD
Journal: Blood
Blood (2010) 116 (21): 1396.
https://doi.org/10.1182/blood.V116.21.1396.1396
Published: 2010
Journal Articles

Population Pharmacokinetics (PK) of Oral Posaconazole (POS) for Antifungal Prophylaxis in Neutropenic Patients with Hematologic Malignancies.

Malaz A. AbuTarif, PhD, Gopal Krishna, PhD, Paul Statkevich, PhD
Journal: Blood
Blood (2007) 110 (11): 2287.
https://doi.org/10.1182/blood.V110.11.2287.2287
Published: 2007